Folate Receptor β (FRβ) Expression on Myeloid Cells and the Impact of Reticuloendothelial System on Folate-Functionalized Nanoparticles’ Biodistribution in Cancer
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Sibel Goksen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Research, Institute of Health Sciences, Hacettepe University, Ankara 06100, Türkiye. Hauptthemen laut MEDLINE: Folic Acid, Folate Receptor 2, Nanoparticles, Myeloid Cells. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HORIZON EUROPE Marie Sklodowska-Curie Actions, Y?ksek?gretim Kurulu, T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu.
Abstract (Originalsprache)
Folate uptake is largely mediated by folate receptor (FR)β, encoded by FOLR2 gene, in myeloid immune cells such as granulocytes, monocytes, and especially in macrophages that constitute the reticuloendothelial system (RES) and infiltrate the tumor microenvironment. Since the myeloid immune compartment dynamically changes during tumorigenesis, it is critical to assess the infiltration status of the tumors by FRβ-expressing myeloid cells to better define the targeting efficacy of folate-functionalized drug delivery systems. On the other hand, clearance by RES is a major limitation for the targeting efficacy of nanoparticles decorated with folate. Therefore, the aims of this study are (i) to determine the amount and subtypes of FRβ+ myeloid cells infiltrating the tumors at different stages, (ii) to compare the amount and subtype of FRβ+ myeloid cells in distinct organs of tumor-bearing and healthy animals, (iii) to test if the cancer-targeting efficacy and biodistribution of a prototypic folate-functionalized nanoparticle associates with the density of FRβ+ myeloid cells. Here, we report that myeloid cell infiltration was enhanced and FRβ was upregulated at distinct stages of tumorigenesis in a mouse breast cancer model. The CD206+ subset of macrophages highly expressed FRβ, prominently both in tumor-bearing and healthy mice. In tumor-bearing mice, the amount of all myeloid cells, but particularly granulocytes, was remarkably increased in the tumor, liver, lungs, spleen, kidneys, lymph nodes, peritoneal cavity, bone marrow, heart, and brain. Compared with macrophages, the level of FRβ was moderate in granulocytes and monocytes. The density of FRβ+ immune cells in the tumor microenvironment was not directly associated with the tumor-targeting efficacy of the folate-functionalized cyclodextrin nanoparticles. The lung was determined as a preferential site of accumulation for folate-functionalized nanoparticles, wherein FRβ+CD206+ macrophages significantly engulfed cyclodextrin nanoparticles. In conclusion, our results demonstrate that the tumor formation augments the FR levels and alters the infiltration and distribution of myeloid immune cells in all organs which should be considered as a major factor influencing the targeting efficacy of nanoparticles for drug delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Research, Institute of Health Sciences, Hacettepe University, Ankara 06100, Türkiye.
- Department of Vaccine Technology, Hacettepe University Vaccine Institute, Ankara 06100, Türkiye.
- Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara 06100, Türkiye.
- Department of Vaccinology, Hacettepe University Vaccine Institute, Ankara 06100, Türkiye.
- Department of Basic Oncology, Hacettepe University Cancer Institute, Ankara 06100, Türkiye.
ORCID-Profile: Sibel Goksen, Gunes Esendagli
Förderung
- HORIZON EUROPE Marie Sklodowska-Curie Actions
- Y?ksek?gretim Kurulu
- T?rkiye Bilimsel ve Teknolojik Arastirma Kurumu
- Hacettepe ?niversitesi
Zitieren
APA
Goksen, S., Varan, G., Bilensoy, E., & Esendagli, G. (2024). Folate Receptor β (FRβ) Expression on Myeloid Cells and the Impact of Reticuloendothelial System on Folate-Functionalized Nanoparticles’ Biodistribution in Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00663
Vancouver
Goksen S, Varan G, Bilensoy E, Esendagli G. Folate Receptor β (FRβ) Expression on Myeloid Cells and the Impact of Reticuloendothelial System on Folate-Functionalized Nanoparticles’ Biodistribution in Cancer. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00663
BibTeX
@article{Goksen2024,
author = {Goksen, Sibel and Varan, Gamze and Bilensoy, Erem and Esendagli, Gunes},
title = {Folate Receptor β (FRβ) Expression on Myeloid Cells and the Impact of Reticuloendothelial System on Folate-Functionalized Nanoparticles’ Biodistribution in Cancer},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00663}
}
EUVIMED